Recent Quotes

Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is Vadadustat, an oral therapy, which is used for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. The company is also developing a HIF-based portfolio of product for the treatment of anemia. Geographically, all the business activity is functioned through the region of United States.

Earnings

Q2 2021		Est.		Actual		Surprise
EPS		(EXPECTED)2021-08-09
REV		(EXPECTED)2021-08-09

Q1 2021		Est.		Actual		Surprise
EPS		-0.360		-0.450		-0.0900
REV		42.840M		52.304M		9.464M

Analyst Ratings

Date	Analyst Firm	Analyst Name	Action	Rating	Action Price	Prior Price	Target

Related Companies

Ticker	Company	Price	Change	Chg %		Mkt Cap
AKBA	Akebia Therapeutics	3.68	0.01	0.27%		589.2M

Akebia Therapeutics Frequently Asked Questions

How do I buy Akebia Therapeutics (AKBA) stock?

You can purchase shares of Akebia Therapeutics (NASDAQ: AKBA) through any online brokerage.

View our list of the best stock brokerages.

Who are Akebia Therapeutics's (AKBA) competitors?

Other companies in Akebia Therapeutics’s space includes: Orchard Therapeutics (NASDAQ:ORTX), Eagle Pharmaceuticals (NASDAQ:EGRX), Atossa Therapeutics (NASDAQ:ATOS), Altimmune (NASDAQ:ALT) and Adaptimmune Therapeutics (NASDAQ:ADAP).

What is the target price for Akebia Therapeutics (AKBA) stock?

The latest price target for Akebia Therapeutics (NASDAQ: AKBA) was reported by Cantor Fitzgerald on March 8, 2021. The analyst firm set a price target for 8.00 expecting AKBA to rise to within 12 months (a possible 117.39% upside). 8 analyst firms have reported ratings in the last year.

Current Stock Price for Akebia Therapeutics (AKBA)?

The stock price for Akebia Therapeutics (NASDAQ: AKBA) is $3.68 last updated Fri Jun 18 2021 20:00:04 GMT+0000 (Coordinated Universal Time).

Does Akebia Therapeutics (AKBA) pay a dividend?

There are no upcoming dividends for Akebia Therapeutics.

When is Akebia Therapeutics (NASDAQ:AKBA) reporting earnings?

Akebia Therapeutics’s Q2 earnings are confirmed for after-market on August 9, 2021.

Is Akebia Therapeutics (AKBA) going to split?

There is no upcoming split for Akebia Therapeutics.

What sector and industry does Akebia Therapeutics (AKBA) operate in?

Akebia Therapeutics is in the Consumer Discretionary sector and Multiline Retail industry. They are listed on the NASDAQ.